This trial is evaluating whether Radiation therapy will improve 2 primary outcomes and 1 secondary outcome in patients with Head Neoplasms. Measurement will happen over the course of CT Simulation to first treatment (about 1 week).
This trial requires 90 total participants across 2 different treatment groups
This trial involves 2 different treatments. Radiation Therapy is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.
The current therapies are more efficient than the pre-existing therapies. However, it is too late to say anything about the possibility of cure of the advanced neurogenic metastatic tumor with these available therapies.
Brain tumours are very diverse, and occur mainly in the adult age group. They most commonly occur in children and adolescents with frequency proportional to age. The most frequent type is gliomas (glioblastoma multiforme). Tumours of the pituitary gland are relatively uncommon and occur mainly in adults. The incidence of pituitary tumours increases with age; more and more elderly people are diagnosed with tumours, and the age group of the 30- to 70-year-old age bracket is an important one from a medical point of view. The most common pituitary tumours are adenomas; a minority of adenomas are malignant.
The most popular treatment for head neoplasms, surgery, can be used to manage localized cases. The most popular option, which was used to treat more than 80% of cases, was surgery. However, head neoplasms are often metastatic. Because a surgery is not possible in most cases, it can be used less often to manage metastatic [brain tumor](https://www.withpower.com/clinical-tri[als](https://www.withpower.com/clinical-trials/als)/brain-tumor)s, brain neoplasms with intracranial extension, and other extracranial tumors that extend to the brain. This treatment approach is known as resection or debulking, though more complex therapies such as cranial irradiation may also be offered. Radiation can produce many side effects requiring careful management. Even metastatic cases can sometimes be managed with surgery.
It is estimated that about 45,000 malignant neoplasms of the central nervous system are diagnosed and about 23,000 people die of such diseases in the United States each year.talmoplasms.
Head and neck cancer results from the interplay of genetics and lifestyle risks. Tobacco is the main substance responsible for most cases of head and neck cancer.
The signs and symptoms of head neoplasms arise principally from the growth of the abnormal brain tissue and may be nonspecific signs such as the presence of headache as well as signs that suggest specific pathology such as the presence of one or more focal neurological deficits on neurological examination. However, the presentation of neoplasms may be more specific such as the presence of a mass or focal neurological deterioration.
The incidence and rate of CNS tumors in this cohort were much more than that found in other series, although the disease-specific survival was very good (<25%).
New therapies that are being explored in clinical trials can have significant potential in treatment of many types of tumors and thus could bring about a new era for treatment options.
Many metastatic and/or unresectable head and neck cancers are commonly treated with radiotherapy plus chemotherapy. The use of radiation therapy in this setting varies according to the degree of response, the extent of disease, the age of the patient, the performance status of the patient, and the type of chemotherapy used. Although there is no optimal regimen, radiosurgery, stereotactic radiosurgery, and other minimally invasive techniques seem to achieve equivalent and higher local control rates than conventional external beam radiotherapy.
In this large and well-defined population-based case-control study, no overall association was detected between neoplasm occurrence in patients with a family history of [head and neck cancer](https://www.withpower.com/clinical-trials/head-and-neck-cancer) and an increased risk of head-and-neck cancer. Head and neck cancer was associated with familial factors suggesting a role for environmental exposures and modifier genes.
Data from a recent study indicate that overall quality of life is improved by treatment with EBRT in patients with surgically treatable head and neck malignancies, with acceptable side effects.
Radiation therapy commonly involves targets outside of the cranial cavity, as shown by the vast majority of cases. Given the current understanding of radiobiology, which indicates all radiation treatment can cause some damage to normal tissues, it seems the vast majority of cases would not cause significant cancer. However, even with the understanding of radiation-induced injury (described in the Radiobiology subsection), radiotherapy can still be a potentially dangerous treatment. A good analogy for radiation therapy is amputation, which requires sacrificing a full hand in order to remove the offending lesion; this is because amputated tissues do not divide and heal as well as intact tissue.